Wyeth launches own generic Protonix, so standstill with Teva void
Israeli generics giant Teva Pharmaceutical Industries' standstill agreement with Wyeth and Altana regarding additional shipments by the former of generic Protonix (pantoprazole sodium) has been terminated as a result of Wyeth's launch of an authorized generic product. The US drug major says that its generic Protonix is being distributed by Prasco, effective January 29.
Teva is currently involved in patent litigation with Wyeth/Altana concerning this product in the US District Court for the District of New Jersey. A trial date has not been set.
In September 2007, the District Court denied a motion filed by Wyeth/Altana for a preliminary injunction related to Teva's pantoprazole tablets. In that decision, the Court found that Wyeth/Altana did not meet its burden of proving likelihood of success on the merits. The two firms have appealed that decision.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze